| 초록 |
Global big pharmaceutical companies identify Absorption-Distribution-Metabolism-Excretion-Toxicity (ADMET)properties in early drug discovery stage to improve poor pharmacokinetics (PK) and bioavailability (BA) that are the majorcause of attrition rate in drug development in 1990s. Attrition rate due to poor PK and BA was around 40% among totalattrition rate. Hence, they intend to assign in-vitro ADME assay evaluations at the early drug discovery stage for findingoptimal ADME chemicals to reduce attrition rate. As a result, attrition rate in 2000s due to poor PK & BA greatlydecreased to less than 8% and the role of Drug-Metabolism and Pharmacokinetics (DMPK) research has changedimportantly during this process. According to this trend, canonical role of DMPK is moving fast to convergence area foroptimization of new drugs. We expressed typical nonclinical work-flow in the 1990s and 2000s and tried to investigatehow non-clinical work-flow changed in early drug discovery stage. The biggest changes are that in-vitro ADME assayswere performed during the early drug discovery stage. In this review, we tried to inform to Korean pharmaceuticalcompany about the world wide paradigm shift in DMPK research. We discussed drug discovery strategies to increase thesuccess rate and the future direction of DMPK research scope |
